Author: Admin

Developer

Ceapro Inc. Reports 2020 First Quarter Financial Results and Highlights

Posted on by Admin

Ceapro Inc. Reports 2020 First Quarter Financial Results and Highlights

(Note: companies that
could be impacted by the content of this article are listed at the base of the
story [desktop version]. This article uses third-party references to provide a
bullish, bearish, and balanced point of view; sources are listed after the
Balanced section.)

– Maintained production operations during COVID-19 pandemic crisis, providing our customers essential products while ensuring the health and safety of our employees –
– R&D activities focused on the development of innovative delivery systems –
– First quarter 2020 sales increased 34% vs. first quarter 2019 –
– Net profit of $1,126,000 for Q1 2020 vs. net loss of $637,000 for Q1 2019 –
EDMONTON, ALBERTA – May 28, 2019 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2020.
“We are very pleased with the progress we have made on multiple fronts during the first quarter of this year, despite the COVID-19 pandemic crisis. While our first quarter financial results were very strong, our focus remains on the health and safety of our associates during these unprecedented times, followed by business continuity. These solid results are a clear testament to the dedication and hard work of every one of our employees during these challenging times and we are very proud of their commitment to support our customers heightened demand by delivering high quality products. Importantly, these results also reflect the sound foundation and the strength of our base business deliberately built over the last few years,” stated Gilles Gagnon, M.Sc., MBA, President and CEO.
Corporate and Operational Highlights
Pipeline Development:
• Received approval from Health Canada for an amendment to the beta glucan clinical trial protocol to allow evaluation of subjects with confirmed pathophysiological condition of hyperlipidemia who voluntary request to be treated with beta glucan only, without regular dosing of statins. This, allowing patients to receive beta glucan as a stand-alone therapy, should accelerate patient enrollment and expand target addressable patient population.
• Received approval from Health Canada Controlled Substances and Cannabis Branch for a research license with medical cannabis for the formulation of unique solid cannabinoid delivery systems using PGX technology.
• Published Results from a collaborative project with University of Alberta researchers in Journal of Supercritical Fluids in an article titled “Preparation of PGX-dried gum arabic and its loading with coQ10 by adsorptive precipitation.”
• Continued to monitor stability studies for liquid beta glucan and avenanthramides produced at a new manufacturing site as well as for the pharmaceutical-grade dry powder formulation of avenanthramides to be used in a human bioavailability study.
• Developed new PGX-dried chemical complexes like sodium alginate and gum arabic impregnated with coenzyme Q10 demonstrating the versatility of the PGX technology and the potential to develop significant bioactives delivery systems.
Technology:
• Advanced conversations with interested potential partners to out-license applications developed using Ceapro’s innovative technology.
• Conducted a technical assessment of available equipment in Europe and North America and are actively evaluating locations for a future commercial scale-up of the PGX technology.
• Advanced research and development efforts to pursue the development of new PGX-dried chemical complexes for potential applications under various forms like pills, capsules, fast dissolving strips and face masks.
• Executed on research collaboration projects with Universities of Alberta and McMaster for the impregnation of various bio actives using PGX-processed dry beta glucan as a potential delivery system for multiple applications in healthcare.
• Subsequent to quarter, announced research project with McMaster University for PGX-processed yeast beta glucan as a potential treatment for COVID-19 patients.
Corporate:
• Hired an international consulting firm to support licensing activities.
• Secured DTC Eligibility for publicly traded shares under Ticker OTCQZ: CRPOF.
• Increased Company exposure through investor relations activities.
Financial Highlights for the First Quarter Ended March 31, 2020
• Total sales of $4,273,000 for the first quarter of 2020 compared to $3,197,000 for the comparative period in 2019; an increase of 34% over last year. Avenanthramides sales volumes increased by 68% for Q1 2020 vs Q1 2019.
• Net income after taxes of $1,126,000 for the first quarter of 2020 compared to a net loss after taxes of $637,000 for the comparative period in 2019.
• Research and Development of $503,000 in Q1 2020 vs $801,000 in 2019. This decreased investment was partly due to a slowdown of recruitment of patients for the beta glucan trial during the pandemic crisis.
• Cash generated from operations of $531,000 in Q1 2020 vs. cash flows generated from operations of $367,000 in Q1 2019.
• Positive working capital balance of $6,263,817 as of March 31, 2020.
“As we respond to the potential impacts and uncertainties of COVID-19 by taking the necessary steps to preserve our financial position, we continue to execute on our transition to a new business model from a contract manufacturer to a biopharmaceutical company. We remain dedicated to executing on our milestones ahead and depending on the pandemic situation, look forward to what we believe will be an exciting year,” concluded Mr. Gagnon.

About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.
For more information contact:
Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: [email protected]
Issuer:
Gilles R. Gagnon, M.Sc., MBA President & CEO T: 780-421-4555
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Continues to Solidify NG-911 Offerings with New Acquisition

Posted on by Admin

Wednesday, May 27, 2020

Comtech Telecommunications Corp. (CMTL)

Continues to Solidify NG-911 Offerings with New Acquisition

Comtech Telecommunications Corp. engages in the design, development, production, and marketing of products, systems, and services for advanced communications solutions in the United States and internationally. It operates in three segments: Telecommunications Transmission, Mobile Data Communications, and RF Microwave Amplifiers. The Telecommunications Transmission segment provides satellite earth station equipment and systems, over-the-horizon microwave systems, and forward error correction technology, which are used in various commercial and government applications, including backhaul of wireless and cellular traffic, broadcasting (including HDTV), IP-based communications traffic, long distance telephony, and secure defense applications. The Mobile Data Communications segment provides mobile satellite transceivers, and computers and satellite earth station network gateways and associated installation, training, and maintenance services; supplies and operates satellite packet data networks, including arranging and providing satellite capacity; and offers microsatellites and related components. The RF Microwave Amplifiers segment designs, develops, manufactures, and markets satellite earth station traveling wave tube amplifiers (TWTA) and broadband amplifiers. Its amplifiers are used in broadcast and broadband satellite communication; defense applications, such as telecommunications systems and electronic warfare systems; and commercial applications comprising oncology treatment systems, as well as to amplify signals carrying voice, video, or data for air-to-satellite-to-ground communications. The company serves satellite systems integrators, wireless and other communication service providers, broadcasters, defense contractors, military, governments, and oil companies. Comtech markets its products through independent representatives and value-added resellers. The company was founded in 1967 and is headquartered in Melville, New York.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New Acquisition. Yesterday, Comtech announced it had acquired NG-911, Inc., a pioneer of next generation 911 solutions for public safety agencies in the Midwest. Terms of the deal were not made public and the financial impact of the acquisition is not material. In connection with the deal, Comtech was awarded several contracts to deploy the Company’s Solacom’s Guardian Call Handling solutions to the 9-1-1 Northern Illinois Next Generation Alliance Consortium valued at more than $15 million over a multi-year period.

    Solidifying NG-911 Position. The acquisition of NG-911 continues to expand and solidify Comtech’s next generation 911 position, in our view. In February, Comtech was selected to provide a Guardian Next Generation 9-1-1 call handling solution to the Northwest Central Dispatch System, an intergovernmental consolidated emergency dispatch system providing 9-1-1 services for several communities in northwest suburban Chicago and received a $ 6.6 million award to upgrade a statewide NG 9-1-1 system for a New England state. Last year, the Company acquired Solacom, received a $100 million NG-911 award from Massachusetts, and…



    Click to get the full report.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Potential Therapy for Pulmonary Fibrosis in COVID-19 Patients

Posted on by Admin

Wednesday, May 27, 2020

Ceapro (CRPOF)(CZO)

Potential Therapy for Pulmonary Fibrosis in COVID-19 Patients

Ceapro, Inc. is a publicly-held (TSX-V: CZO, OTCQX: CRPOF) Canadian biotechnology company developing and commercializing “active ingredients” for the healthcare and cosmetic industries. Ceapro’s active ingredients are primarily derived from oats and other renewable plant resources. The Company utilizes its proprietary plant extraction-based manufacturing process to supply active ingredients based on “oat beta glucan and avenanthramides”. Ceapro has patented a technology known as “Pressurized Gas eXpanded (PGX) technology”, which has superior features when compared to conventional drying and purification technologies. Using PGX technology, Ceapro generates novel biopolymers and biocomposites with micro/nanoparticles.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ceapro expands collaboration with McMaster University. Under the new collaboration agreement, Ceapro will sponsor the development of an inhalable therapeutic based on “PGXprocessed yeast beta glucan” (PGX-YBG) for the treatment of pulmonary fibrosis in COVID19 patients. In preclinical models, PGX-YBG has shown immunomodulatory properties.

    Versatility of Ceapro’s proprietary PGX Technology. PGX technology utilizes the unique properties of a PGX liquid consisting of pressurized carbon dioxide and ethanol to dry aqueous polymer solutions at mild operating conditions in a spray chamber, which allows the production of ultra thin, high value biopolymers with multiple medical and…


    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Neovasc Removes Financing Overhang

Posted on by Admin

Wednesday, May 27, 2020

Neovasc (NVCN)(NVCN:CA)

Neovasc Removes Financing Overhang

As of April 24, 2020, Noble Capital Markets research on Neovasc is published under ticker symbols (NVCN and NVCN:CA). The price target is in USD and based on ticker symbol NVCN. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Neovasc Inc is a specialty medical device company. The company develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina. Neovasc is developing the Tiara for the treatment of mitral valve disease. Neovasc operates its business in one segment.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Retiring 2017 Notes. Neovasc’s management yesterday provided a corporate update and announced several agreements, including a $5 mm financing, and the retirement of 2017 Notes (which had onerous provisions), which we believe improves the Company’s financial position and revamps its capital structure.

The Reducer for the Treatment of Refractory Angina. Neovasc is seeking FDA approval to commercialize the Reducer for the treatment of refractory angina in the United States. Management indicated that Pre-Market Approval (PMA) review is progressing as expected. The Company just…



Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Comtech Telecommunications Corp. (CMTL) – Continues to Solidify NG-911 Offerings with New Acquisition

Posted on by Admin

Wednesday, May 27, 2020

Comtech Telecommunications Corp. (CMTL)

Continues to Solidify NG-911 Offerings with New Acquisition

Comtech Telecommunications Corp. engages in the design, development, production, and marketing of products, systems, and services for advanced communications solutions in the United States and internationally. It operates in three segments: Telecommunications Transmission, Mobile Data Communications, and RF Microwave Amplifiers. The Telecommunications Transmission segment provides satellite earth station equipment and systems, over-the-horizon microwave systems, and forward error correction technology, which are used in various commercial and government applications, including backhaul of wireless and cellular traffic, broadcasting (including HDTV), IP-based communications traffic, long distance telephony, and secure defense applications. The Mobile Data Communications segment provides mobile satellite transceivers, and computers and satellite earth station network gateways and associated installation, training, and maintenance services; supplies and operates satellite packet data networks, including arranging and providing satellite capacity; and offers microsatellites and related components. The RF Microwave Amplifiers segment designs, develops, manufactures, and markets satellite earth station traveling wave tube amplifiers (TWTA) and broadband amplifiers. Its amplifiers are used in broadcast and broadband satellite communication; defense applications, such as telecommunications systems and electronic warfare systems; and commercial applications comprising oncology treatment systems, as well as to amplify signals carrying voice, video, or data for air-to-satellite-to-ground communications. The company serves satellite systems integrators, wireless and other communication service providers, broadcasters, defense contractors, military, governments, and oil companies. Comtech markets its products through independent representatives and value-added resellers. The company was founded in 1967 and is headquartered in Melville, New York.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New Acquisition. Yesterday, Comtech announced it had acquired NG-911, Inc., a pioneer of next generation 911 solutions for public safety agencies in the Midwest. Terms of the deal were not made public and the financial impact of the acquisition is not material. In connection with the deal, Comtech was awarded several contracts to deploy the Company’s Solacom’s Guardian Call Handling solutions to the 9-1-1 Northern Illinois Next Generation Alliance Consortium valued at more than $15 million over a multi-year period.

    Solidifying NG-911 Position. The acquisition of NG-911 continues to expand and solidify Comtech’s next generation 911 position, in our view. In February, Comtech was selected to provide a Guardian Next Generation 9-1-1 call handling solution to the Northwest Central Dispatch System, an intergovernmental consolidated emergency dispatch system providing 9-1-1 services for several communities in northwest suburban Chicago and received a $ 6.6 million award to upgrade a statewide NG 9-1-1 system for a New England state. Last year, the Company acquired Solacom, received a $100 million NG-911 award from Massachusetts, and…



    Click to get the full report.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Ceapro (CRPOF)(CZO) – Potential Therapy for Pulmonary Fibrosis in COVID-19 Patients

Posted on by Admin

Wednesday, May 27, 2020

Ceapro (CRPOF)(CZO)

Potential Therapy for Pulmonary Fibrosis in COVID-19 Patients

Ceapro, Inc. is a publicly-held (TSX-V: CZO, OTCQX: CRPOF) Canadian biotechnology company developing and commercializing “active ingredients” for the healthcare and cosmetic industries. Ceapro’s active ingredients are primarily derived from oats and other renewable plant resources. The Company utilizes its proprietary plant extraction-based manufacturing process to supply active ingredients based on “oat beta glucan and avenanthramides”. Ceapro has patented a technology known as “Pressurized Gas eXpanded (PGX) technology”, which has superior features when compared to conventional drying and purification technologies. Using PGX technology, Ceapro generates novel biopolymers and biocomposites with micro/nanoparticles.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ceapro expands collaboration with McMaster University. Under the new collaboration agreement, Ceapro will sponsor the development of an inhalable therapeutic based on “PGXprocessed yeast beta glucan” (PGX-YBG) for the treatment of pulmonary fibrosis in COVID19 patients. In preclinical models, PGX-YBG has shown immunomodulatory properties.

    Versatility of Ceapro’s proprietary PGX Technology. PGX technology utilizes the unique properties of a PGX liquid consisting of pressurized carbon dioxide and ethanol to dry aqueous polymer solutions at mild operating conditions in a spray chamber, which allows the production of ultra thin, high value biopolymers with multiple medical and…


    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Neovasc (NVCN)(NVCN:CA) – Neovasc Removes Financing Overhang

Posted on by Admin

Wednesday, May 27, 2020

Neovasc (NVCN)(NVCN:CA)

Neovasc Removes Financing Overhang

As of April 24, 2020, Noble Capital Markets research on Neovasc is published under ticker symbols (NVCN and NVCN:CA). The price target is in USD and based on ticker symbol NVCN. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Neovasc Inc is a specialty medical device company. The company develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina. Neovasc is developing the Tiara for the treatment of mitral valve disease. Neovasc operates its business in one segment.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Retiring 2017 Notes. Neovasc’s management yesterday provided a corporate update and announced several agreements, including a $5 mm financing, and the retirement of 2017 Notes (which had onerous provisions), which we believe improves the Company’s financial position and revamps its capital structure.

The Reducer for the Treatment of Refractory Angina. Neovasc is seeking FDA approval to commercialize the Reducer for the treatment of refractory angina in the United States. Management indicated that Pre-Market Approval (PMA) review is progressing as expected. The Company just…



Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Visible Growth Drivers

Posted on by Admin

Tuesday, May 26, 2020

Ely Gold Royalties (ELYGF)(ELY:CA)

Visible Growth Drivers

As of April 24, 2020, Noble Capital Markets research on Ely Gold Royalties is published under ticker symbols (ELYGF and ELY:CA). The price target is in USD and based on ticker symbol ELYGF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Ely Gold Royalties Inc is an emerging royalty company with producing and development assets focused in Nevada and the Western US. It offers shareholders a low-risk leverage to the current price of gold and low-cost access to long-term gold royalties.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ely substantially completes acquisition of VEK Associates.  Ely Gold Royalties has substantially completed its acquisition of VEK Associates and has closed on the acquisition of 92.4% of the VEK shares outstanding. The remaining 7.6% of VEK shares are expected to be acquired pending the completion of share transfer documentation. VEK’s principal assets are comprised of five royalty properties, all of which are currently leased. Four of the leases are with Nevada Gold Mines, a joint venture 61.5% owned and operated by Barrick Gold Corporation and 31.5% owned by Newmont Corporation, and the other lease is with SSR Mining Inc.

    Private placement raises C$17,250,00 to fund growth initiatives. On May 21, Ely Gold Royalties closed a brokered private placement offering of 21,562,500 units at a price of C$0.80 per unit for gross proceeds of C$17,250,000. Following the offering, we estimate Ely Gold has 157,286,496 shares outstanding and 197,120,376 on a fully diluted basis. The company intends to use the net proceeds for exploration, royalty acquisitions and…



    Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Emerging as a Leader in Cancer Gene Therapy

Posted on by Admin

Tuesday, May 26, 2020

Genprex Inc.(GNPX)

Emerging as a Leader in Cancer Gene Therapy

Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Unique Gene Therapy Technology. We believe that Genprex will emerge as a leader in the area of gene therapy for the treatment of cancer. Genprex is developing a unique platform technology consisting of the use of lipid nanoparticles designed to restore normal tumor suppressor protein levels in cancer cells to induce apoptosis (programmed cell death), inhibit tumor progression and prolong survival of cancer patients.

    GEN-001 for the Treatment of Lung Cancer. Genprex’s lead product, GEN-001, in combination with AstraZeneca’s Tagrisso or Merck’s Keytruda, will be evaluated in Phase I/II clinical trials for the treatment of non-small cell lung cancer (NSCLC). Previous clinical results showed a disease control rate (DCR) of….


    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Ely Gold Royalties (ELYGF)(ELY:CA) – Visible Growth Drivers

Posted on by Admin

Tuesday, May 26, 2020

Ely Gold Royalties (ELYGF)(ELY:CA)

Visible Growth Drivers

As of April 24, 2020, Noble Capital Markets research on Ely Gold Royalties is published under ticker symbols (ELYGF and ELY:CA). The price target is in USD and based on ticker symbol ELYGF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Ely Gold Royalties Inc is an emerging royalty company with producing and development assets focused in Nevada and the Western US. It offers shareholders a low-risk leverage to the current price of gold and low-cost access to long-term gold royalties.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ely substantially completes acquisition of VEK Associates.  Ely Gold Royalties has substantially completed its acquisition of VEK Associates and has closed on the acquisition of 92.4% of the VEK shares outstanding. The remaining 7.6% of VEK shares are expected to be acquired pending the completion of share transfer documentation. VEK’s principal assets are comprised of five royalty properties, all of which are currently leased. Four of the leases are with Nevada Gold Mines, a joint venture 61.5% owned and operated by Barrick Gold Corporation and 31.5% owned by Newmont Corporation, and the other lease is with SSR Mining Inc.

    Private placement raises C$17,250,00 to fund growth initiatives. On May 21, Ely Gold Royalties closed a brokered private placement offering of 21,562,500 units at a price of C$0.80 per unit for gross proceeds of C$17,250,000. Following the offering, we estimate Ely Gold has 157,286,496 shares outstanding and 197,120,376 on a fully diluted basis. The company intends to use the net proceeds for exploration, royalty acquisitions and…



    Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Genprex Inc. (GNPX) – Emerging as a Leader in Cancer Gene Therapy

Posted on by Admin

Tuesday, May 26, 2020

Genprex Inc.(GNPX)

Emerging as a Leader in Cancer Gene Therapy

Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Unique Gene Therapy Technology. We believe that Genprex will emerge as a leader in the area of gene therapy for the treatment of cancer. Genprex is developing a unique platform technology consisting of the use of lipid nanoparticles designed to restore normal tumor suppressor protein levels in cancer cells to induce apoptosis (programmed cell death), inhibit tumor progression and prolong survival of cancer patients.

    GEN-001 for the Treatment of Lung Cancer. Genprex’s lead product, GEN-001, in combination with AstraZeneca’s Tagrisso or Merck’s Keytruda, will be evaluated in Phase I/II clinical trials for the treatment of non-small cell lung cancer (NSCLC). Previous clinical results showed a disease control rate (DCR) of….


    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Thinking Big

Posted on by Admin

Friday, May 22, 2020

Sierra Metals (SMTS)(SMT:CA)

Thinking Big

As of April 24, 2020, Noble Capital Markets research on Sierra Metals is published under ticker symbols (SMTS and SMT:CA). The price target is in USD and based on ticker symbol SMTS. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Sierra Metals Inc is a precious and base metals producer in Latin America. The company acquires, explores, extracts, and produces mineral concentrates consisting of silver, copper, lead, zinc and gold in Mexico and Peru. Its activity includes the operation of the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico. Yauricocha is an underground polymetallic mine using the sublevel block caving and cut-and-fill mining methods. Bolivar is a copper-silver-zinc-gold underground mine using room-and-pillar mining method. The majority of the revenue is earned by selling of the mineral concentrates to its customers in Peru.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    CEO appointment marks next chapter in Sierra Metals’ development. Sierra Metals appointed Mr. Luis Marchese as Chief Executive Officer effective June 1 replacing Mr. Igor Gonzales whose voluntary resignation is effective May 31. Under Mr. Gonzales, Sierra Metals successfully completed significant production expansions at the Yauricocha, Bolivar and Cusi mines along with associated resource and reserve expansions. We believe Mr. Marchese will build on Mr. Gonzales’ work and broaden the focus to consider strategic partnerships that could help accelerate development of potential large-scale copper porphyry projects that could create significant value for Sierra Metals shareholders. The company has been executing well operationally and Mr. Marchese has an impressive record of successfully championing large scale copper projects and working with multiple strategic partners.

    Capacity expansions support earnings and cash flow growth. Production capacity has increased 57% from processing 5,375 tonnes per day in 2015 to 8,450 tonnes per day in 2019 for a compound annual growth rate of 12.0%. Production capacity is expected to end 2020 at 9,800 tonnes per day with the potential for additional low-cost expansions. While base metals prices are currently low, most of the capital for recent planned expansions has been spent and we expect the company to begin generating…


    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Sierra Metals (SMTS)(SMT:CA) – Thinking Big

Posted on by Admin

Friday, May 22, 2020

Sierra Metals (SMTS)(SMT:CA)

Thinking Big

As of April 24, 2020, Noble Capital Markets research on Sierra Metals is published under ticker symbols (SMTS and SMT:CA). The price target is in USD and based on ticker symbol SMTS. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Sierra Metals Inc is a precious and base metals producer in Latin America. The company acquires, explores, extracts, and produces mineral concentrates consisting of silver, copper, lead, zinc and gold in Mexico and Peru. Its activity includes the operation of the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico. Yauricocha is an underground polymetallic mine using the sublevel block caving and cut-and-fill mining methods. Bolivar is a copper-silver-zinc-gold underground mine using room-and-pillar mining method. The majority of the revenue is earned by selling of the mineral concentrates to its customers in Peru.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    CEO appointment marks next chapter in Sierra Metals’ development. Sierra Metals appointed Mr. Luis Marchese as Chief Executive Officer effective June 1 replacing Mr. Igor Gonzales whose voluntary resignation is effective May 31. Under Mr. Gonzales, Sierra Metals successfully completed significant production expansions at the Yauricocha, Bolivar and Cusi mines along with associated resource and reserve expansions. We believe Mr. Marchese will build on Mr. Gonzales’ work and broaden the focus to consider strategic partnerships that could help accelerate development of potential large-scale copper porphyry projects that could create significant value for Sierra Metals shareholders. The company has been executing well operationally and Mr. Marchese has an impressive record of successfully championing large scale copper projects and working with multiple strategic partners.

    Capacity expansions support earnings and cash flow growth. Production capacity has increased 57% from processing 5,375 tonnes per day in 2015 to 8,450 tonnes per day in 2019 for a compound annual growth rate of 12.0%. Production capacity is expected to end 2020 at 9,800 tonnes per day with the potential for additional low-cost expansions. While base metals prices are currently low, most of the capital for recent planned expansions has been spent and we expect the company to begin generating…


    Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.